BBUSvsBIS
JPMorgan BetaBuilders U.S. Equity ETF against ProShares UltraShort Nasdaq Biotechnology — the fee, the flows, the book, and a year head-to-head.
Head to head
| BBUS | BIS | |
|---|---|---|
| Expense ratio | 0.020% | 0.95% |
| Assets | $9.7B | $2M |
| Net flow, 1 month | +$257M | — |
| Net flow, 1 year | +$2.5B | +$1K |
| Return, YTD | +12.9% | -43.8% |
| Return, 1 year | +11.9% | -52.4% |
| Avg daily volume | 256K | 11K |
| Holdings | 575 | 7 |
| Listed | Mar 11, 2019 | Apr 9, 2010 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS